# Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes

> **NCT01009580** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 447 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/insulin aspart
- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT01009580
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-05
- **Primary completion:** 2010-08-23
- **Final completion:** 2010-08-23
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009580, "Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01009580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*